Sana Biotechnology Inc. (SANA) continues to draw attention for its progress across multiple cell therapy programs, with recent regulatory and clinical developments positioning the company for key milestones over the next 12 to 18 months.
Shares recently traded around $3.39, reflecting a strong recovery from earlier lows, though still below the 52-week high of $7.30.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.